32 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Discovery of Aryl Sulfonamides as Isoform-Selective Inhibitors of NaV1.7 with Efficacy in Rodent Pain Models.

Xenon Pharmaceuticals
Discovery of triazolone derivatives as novel, potent stearoyl-CoA desaturase-1 (SCD1) inhibitors.

Xenon Pharmaceuticals
The discovery of benzenesulfonamide-based potent and selective inhibitors of voltage-gated sodium channel Na(v)1.7.

Xenon Pharmaceuticals
Systematic evaluation of amide bioisosteres leading to the discovery of novel and potent thiazolylimidazolidinone inhibitors of SCD1 for the treatment of metabolic diseases.

Xenon Pharmaceuticals
Discovery of thiazolylpyridinone SCD1 inhibitors with preferential liver distribution and reduced mechanism-based adverse effects.

Xenon Pharmaceuticals
Discovery of XEN445: a potent and selective endothelial lipase inhibitor raises plasma HDL-cholesterol concentration in mice.

Xenon Pharmaceuticals
Discovery of piperazin-1-ylpyridazine-based potent and selective stearoyl-CoA desaturase-1 inhibitors for the treatment of obesity and metabolic syndrome.

Xenon Pharmaceuticals
Discovery of benzylisothioureas as potent divalent metal transporter 1 (DMT1) inhibitors.

Xenon Pharmaceuticals
Synthesis and biological evaluation of substituted pyrazoles as blockers of divalent metal transporter 1 (DMT1).

Xenon Pharmaceuticals
Discovery of XEN907, a spirooxindole blocker of NaV1.7 for the treatment of pain.

Xenon Pharmaceuticals
Identification of Selective Acyl Sulfonamide-Cycloalkylether Inhibitors of the Voltage-Gated Sodium Channel (Na

Xenon Pharmaceuticals
Methyl-containing pharmaceuticals: Methylation in drug design.

Xenon Pharmaceuticals
Identification of aryl sulfonamides as novel and potent inhibitors of Na

Xenon Pharmaceuticals
Identification of CNS-Penetrant Aryl Sulfonamides as Isoform-Selective Na

Xenon Pharmaceuticals
Applications of amide isosteres in medicinal chemistry.

Xenon Pharmaceuticals
Design of Conformationally Constrained Acyl Sulfonamide Isosteres: Identification of N-([1,2,4]Triazolo[4,3- a]pyridin-3-yl)methane-sulfonamides as Potent and Selective hNa

Xenon Pharmaceuticals
TETRAHYDROTHIENOPYRIMIDINESULFONAMIDE COMPOUNDS

Modulus Discovery
7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant IDH1 and IDH2 inhibitors

Eli Lilly
Thienodiazepine derivatives and application thereof

Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang)
Substituted piperidine compound and use thereof

Takeda Pharmaceutical
ASK1 inhibiting agents

Biogen Ma
6-aminopyridin-3-yl thiazoles as modulators of RORγT

Janssen Pharmaceutica
Heterocyclic compounds as kinase inhibitors

Translational Drug Development
Morphan and morphinan analogues, and methods of use

Alkermes Pharma Ireland
Bicyclic heterocycles as FGFR4 inhibitors

Incyte
5-oxa-2-azabicyclo[2.2.2]OCTAN-4-yl and 5-oxa-2-azabicyclo[2.2.1]heptan-4-yl derivatives

Hoffmann-La Roche
Hexahydrodibenzo[a,g]quinolizine compound, preparation method thereof, pharmaceutical composition and use thereof

Shanghai Institute of Material Medica, Chinese Academy of Sciences
P38MAP kinase inhibitors

Respivert
Nitrogen containing morphinan derivatives and the use thereof

Purdue Pharma
Novel Inhibitor Binding Site Discovery on HIV-1 Capsid N-Terminal Domain by NMR and X-ray Crystallography.

Boehringer Ingelheim (Canada)
An alternative purification method for human serum paraoxonase 1 and its interactions with sulfonamides.

Ataturk University